Shock-like symptoms rarely occur. Administration should be discontinued if such a case.
Respiratory depression may occasionally occur. If these symptoms occur artificial Respiration or administration of Dimorpholamine should be made.
Occasionally palpitation, chills, chest pain, decreases in blood pressure arrhythmia, rarely affection on cardiovascular system may occur.
Drowsiness, lethargy, headache, lightheadedness, excitement, tremor, tinnitus, irritability, fatigue, sweating, dizziness, paraesthesia, disorientation, depression, urinary retention and thirst may infrequently occur.
Occasionally vomiting, nausea, gastrointestinal fullness, borborygmus may occur.
The drug dependence was not recognized in animal studies. But in case of prolonged use and increased-dose, close observation and careful administration should be initiated.
Pyrexia, flushing, chills, urticarial, injection site irritation and excessive bronchial secretion may occur.
Treatment of Adverse Reactions:
In acute poisoning by an opioid taken by mouth, the stomach should be emptied. A laxative may be given to aid peristalsis.
Intensive supportive therapy may be required to correct respiratory failure and shock.
NALOXONE Hydrochloride, a specific antagonist, used to counteract very rapidly the severe respiratory depression and coma produced by excessive doses of opioid analgesic. A dose of 0.4 to 2 mg is given by intravenous injection, repeated at intervals of 2 to 3 minutes. If necessary, up to 10 mg. It may also be given subcutaneously or intramuscularly or by intravenous infusion.
NALORPHIBE Hydrobromide reverses severe opioid- induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other central non-opioid Depressants. A close of 5 to 10 mg is given by intravenous injection, repeated every 10 to 15 minutes as necessary until respiration is restored or maximum total dosage of 40 mg has been given. Treatment may be repeated if a relapsed occurs. Single dose of up to 40 mg have occasionally been given in severe poisoning. It may also be given intramuscularly or subcutaneously.
LEVAILORPHAN Tartrate also reverses severe opioid-induce respiratory depression but may exacerbate respiratory depressions such as that induced by alcohol or other central non-opioid depressants. For the treatment of overdosage, an initial dose of 1 to 2 mg followed by 1 or 2 doses of 0.5 mg at intervals of 5 to 15 minutes is given intravenously but it may also be given subcutaneously or intramuscularly. It has also been used to reserve opioid central depression resulting from the use of opioids during surgery and to reverse neonatal respiratory depression following administration of opioid analgesics to the mother during labor.